MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today that it has appointed Dr Ian Nisbet to the position of Vice-President of Oncology. Dr Nisbet will commence immediately with the company on a fractional basis and will assist with management of ChemGenex’s clinical programs, focusing on regulatory approval and commercialization of Ceflatonin® in the USA and Europe.
